title: Tumor growth inhibition by sonodynamic therapy using a novel sonosensitizer.
abstract: Sonodynamic therapy (SDT) with low-intensity ultrasound combined with a sonosensitizer may be a promising approach to cancer therapy. Use of ultrasound has the advantage of being noninvasive, with deep-penetration properties, and convenient because of the low or no sensitivity of sonosensitizers to light. In this study, SDT with a novel sonosensitizer (a porphyrin derivative) was evaluated in vitro and in vivo. Ultrasound irradiation with a sonosensitizer elicited potent sonotoxicity in vitro without the danger of phototoxicity. The sonotoxic effect was mediated by reactive oxygen species (ROS) and was reduced by ROS scavengers. Cell membrane lipid peroxidation increased significantly just after ultrasound irradiation with a sonosensitizer, but there was no increase in apoptosis. In an in vivo mouse xenograft model, SDT with a sonosensitizer markedly inhibited tumor cell growth. The skin hypersensitivity after light exposure was not observed in a sonosensitizer-treatment group, consistent with the in vitro findings. These results suggest that ROS generated by SDT with a sensitizer can damage tumor cells, resulting in necrosis and prevention of tumor growth. This noninvasive treatment with no adverse effects such as skin sensitivity is therefore promising for therapy of cancers located deep within patients.
authors.affiliation: Department of Biochemistry, Faculty of Medicine, Fukuoka University, Jonan-ku, Fukuoka, Japan.
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Tsuru
authors.forename: Hirotomo
authors.initials: H
authors.lastname: Shibaguchi
authors.forename: Motomu
authors.initials: M
authors.lastname: Kuroki
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Yamashita
authors.forename: Masahide
authors.initials: M
authors.lastname: Kuroki
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D017209:Apoptosis; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D006801:Humans; D015227:Lipid Peroxidation; D008315:Malondialdehyde / Q000378:metabolism; D008665:Metalloporphyrins / Q000627:therapeutic use* / Q000633:toxicity; D051379:Mice; D016513:Mice, SCID; D009336:Necrosis / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D011166:Porphyrins / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D017382:Reactive Oxygen Species / Q000378:metabolism; D013010:Sonication; D013016:Sound; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays
chemical_list: C577434:7,12-bis(1-(2-(2-hydroxyethoxy)ethoxy)ethyl)-3,8,13,17-tetramethylporphyrin-2,18-dipropionatomanganese; D000970:Antineoplastic Agents; D008665:Metalloporphyrins; D017319:Photosensitizing Agents; D011166:Porphyrins; D017382:Reactive Oxygen Species; C081908:ATX 70; D008315:Malondialdehyde